Q-omics provides the consensus-scored RBMX2P3 profile across patient tissues and cancer cell-line models. RBMX2P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RBMX2P3 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, RBMX2P3 RNA expression shows 7,352 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CHOL, LIHC, and GBM as cancer lineages where RBMX2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMX2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMX2P3 survival associations across molecular data types. RBMX2P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMX2P3 RNA expression–survival associations across cancer types. High RBMX2P3 expression shows unfavorable associations in CHOL, LUSC, LUAD and ACC, but favorable associations in CESC and KIRP. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for RBMX2P3 RNA expression.
This table summarizes RBMX2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMX2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMX2P3 shows higher tumor expression in LIHC. The LIHC box plot shows higher RBMX2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .013).
This table shows molecular features associated with RBMX2P3 in patient tissues and cancer cell lines. In patient samples, RBMX2P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
